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INTRADERMAL ADMINISTRATION OF SYNTHETIC DNA VACCINES INDUCE ROBUST CELLULAR AND 
HUMORAL IMMUNE RESPONSES 
 




There has long been an interest by health agencies such as Program for Appropriate Technology in Health 
(PATH) and the World Health Organization (WHO) to deliver vaccines by the intradermal route (ID). The skin is 
full of immunological cells, most notably antigen presenting cells.  Therefore, ID injection may be an efficient 
means of inducing an immune response to vaccines.  Inovio has developed ID injection followed by a shallow in 
vivo electroporation (ID-EP) for synthetic DNA vaccine delivery.  We have tested a number of our vaccines in 
clinical trials using the ID-EP delivery system including vaccines targeted against HIV, ZIKA virus and EBOLA 
virus. The success of the ID method takes on particular importance for a vaccine that will be used in an 
emergency setting such as during a possible Ebola virus outbreak.  Such a vaccine will need to quickly induce 
robust, protective immune responses.  INO-4201, our DNA based Zaire Ebolavirus (EBOV) vaccine, was 
analyzed following ID delivery. Immune responses generated by INO-4201 after the 2mg intradermal 
administration using the Cellectra in vivo electroporation device in volunteers revealed the induction of robust 
Ebola virus GP-specific antibodies, CD4+ as well as CD8+ T cell responses.  Specifically, 100% 
seroconversion, as gauged by binding ELISA, was detected after two doses of INO-4201.  The reciprocal 
geometric mean endpoint titer at that time was 39,664.20 and was boosted by administration of the third dose to 
46,968.00.  Examination of the EBOLA virus GP specific T cell response as assessed by Interferon gamma 
(IFNγ) ELISpot revealed a mean peak response magnitude of 295.3 SFU per 10^6 PBMCs. Importantly, the 
induction of robust immune response by ID-EP was mirrored in the ZIKA virus and HIV DNA vaccine clinical 
trials.  These results indicate that ID methods to deliver DNA-based vaccines are important for further clinical 
development.  
 
